nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—EIF4E—renal system—nephrolithiasis	0.028	0.127	CbGeAlD
Sirolimus—EIF4E—kidney—nephrolithiasis	0.027	0.123	CbGeAlD
Sirolimus—Anorectal disorder—Hydrochlorothiazide—nephrolithiasis	0.0156	0.0289	CcSEcCtD
Sirolimus—Creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.0156	0.0289	CcSEcCtD
Sirolimus—CYP3A4—urine—nephrolithiasis	0.013	0.0589	CbGeAlD
Sirolimus—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.0121	0.0505	CbGpPWpGaD
Sirolimus—Blood creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.0119	0.0221	CcSEcCtD
Sirolimus—Hyperlipidaemia—Hydrochlorothiazide—nephrolithiasis	0.0114	0.0211	CcSEcCtD
Sirolimus—CYP3A7-CYP3A51P—nephron tubule—nephrolithiasis	0.0113	0.0511	CbGeAlD
Sirolimus—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.0112	0.047	CbGpPWpGaD
Sirolimus—MTOR—renal system—nephrolithiasis	0.0108	0.0491	CbGeAlD
Sirolimus—MTOR—kidney—nephrolithiasis	0.0105	0.0474	CbGeAlD
Sirolimus—Glycosuria—Hydrochlorothiazide—nephrolithiasis	0.0101	0.0187	CcSEcCtD
Sirolimus—FKBP1A—renal system—nephrolithiasis	0.00973	0.0441	CbGeAlD
Sirolimus—CYP3A7-CYP3A51P—cortex of kidney—nephrolithiasis	0.00964	0.0437	CbGeAlD
Sirolimus—FKBP1A—kidney—nephrolithiasis	0.00941	0.0427	CbGeAlD
Sirolimus—SLC47A1—nephron tubule—nephrolithiasis	0.0092	0.0417	CbGeAlD
Sirolimus—FKBP1A—cortex of kidney—nephrolithiasis	0.00916	0.0416	CbGeAlD
Sirolimus—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.00885	0.0164	CcSEcCtD
Sirolimus—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.00885	0.0164	CcSEcCtD
Sirolimus—Gout—Hydrochlorothiazide—nephrolithiasis	0.00879	0.0163	CcSEcCtD
Sirolimus—EIF4E—Signaling by Insulin receptor—ATP6V0A4—nephrolithiasis	0.00875	0.0366	CbGpPWpGaD
Sirolimus—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.00868	0.0161	CcSEcCtD
Sirolimus—Bone pain—Hydrochlorothiazide—nephrolithiasis	0.00857	0.0159	CcSEcCtD
Sirolimus—SLC47A1—renal system—nephrolithiasis	0.00836	0.0379	CbGeAlD
Sirolimus—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.00836	0.0155	CcSEcCtD
Sirolimus—SLCO1B1—renal system—nephrolithiasis	0.00826	0.0374	CbGeAlD
Sirolimus—SLC47A1—kidney—nephrolithiasis	0.00808	0.0367	CbGeAlD
Sirolimus—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00806	0.0149	CcSEcCtD
Sirolimus—SLCO1B1—kidney—nephrolithiasis	0.00798	0.0362	CbGeAlD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00792	0.0331	CbGpPWpGaD
Sirolimus—SLC47A1—cortex of kidney—nephrolithiasis	0.00787	0.0357	CbGeAlD
Sirolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00778	0.0325	CbGpPWpGaD
Sirolimus—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.00775	0.0143	CcSEcCtD
Sirolimus—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.0075	0.0139	CcSEcCtD
Sirolimus—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00742	0.0137	CcSEcCtD
Sirolimus—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.00742	0.0137	CcSEcCtD
Sirolimus—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.00731	0.0135	CcSEcCtD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00724	0.0303	CbGpPWpGaD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00724	0.0303	CbGpPWpGaD
Sirolimus—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00685	0.0127	CcSEcCtD
Sirolimus—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.00678	0.0126	CcSEcCtD
Sirolimus—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00672	0.0124	CcSEcCtD
Sirolimus—Injury—Hydrochlorothiazide—nephrolithiasis	0.00648	0.012	CcSEcCtD
Sirolimus—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00634	0.0117	CcSEcCtD
Sirolimus—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.00631	0.0117	CcSEcCtD
Sirolimus—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00629	0.0116	CcSEcCtD
Sirolimus—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.00626	0.0116	CcSEcCtD
Sirolimus—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00598	0.0111	CcSEcCtD
Sirolimus—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.00586	0.0109	CcSEcCtD
Sirolimus—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00575	0.0106	CcSEcCtD
Sirolimus—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00564	0.0104	CcSEcCtD
Sirolimus—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00558	0.0103	CcSEcCtD
Sirolimus—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.0055	0.0102	CcSEcCtD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00549	0.023	CbGpPWpGaD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00549	0.023	CbGpPWpGaD
Sirolimus—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00544	0.0101	CcSEcCtD
Sirolimus—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00542	0.01	CcSEcCtD
Sirolimus—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00538	0.00996	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00536	0.00993	CcSEcCtD
Sirolimus—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00527	0.00976	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00525	0.00972	CcSEcCtD
Sirolimus—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00518	0.00959	CcSEcCtD
Sirolimus—FGF2—Endochondral Ossification—PTH—nephrolithiasis	0.00518	0.0216	CbGpPWpGaD
Sirolimus—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00515	0.00953	CcSEcCtD
Sirolimus—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00515	0.00953	CcSEcCtD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.0051	0.0213	CbGpPWpGaD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.0051	0.0213	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—AQP1—nephrolithiasis	0.00506	0.0212	CbGpPWpGaD
Sirolimus—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00505	0.00934	CcSEcCtD
Sirolimus—FGF2—Signaling by Insulin receptor—ATP6V0A4—nephrolithiasis	0.00486	0.0203	CbGpPWpGaD
Sirolimus—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00481	0.00891	CcSEcCtD
Sirolimus—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00481	0.00891	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00479	0.00886	CcSEcCtD
Sirolimus—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00476	0.0088	CcSEcCtD
Sirolimus—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00474	0.00878	CcSEcCtD
Sirolimus—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00469	0.00867	CcSEcCtD
Sirolimus—CYP3A5—nephron tubule—nephrolithiasis	0.00466	0.0211	CbGeAlD
Sirolimus—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00464	0.00859	CcSEcCtD
Sirolimus—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00462	0.00854	CcSEcCtD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00455	0.019	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00452	0.0189	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00452	0.0189	CbGpPWpGaD
Sirolimus—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.0045	0.00833	CcSEcCtD
Sirolimus—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00446	0.00826	CcSEcCtD
Sirolimus—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00446	0.00826	CcSEcCtD
Sirolimus—Sweating—Hydrochlorothiazide—nephrolithiasis	0.0044	0.00814	CcSEcCtD
Sirolimus—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00438	0.0081	CcSEcCtD
Sirolimus—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00433	0.00801	CcSEcCtD
Sirolimus—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00431	0.00797	CcSEcCtD
Sirolimus—CYP3A5—renal system—nephrolithiasis	0.00424	0.0192	CbGeAlD
Sirolimus—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00413	0.00765	CcSEcCtD
Sirolimus—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.0041	0.00759	CcSEcCtD
Sirolimus—CYP3A5—kidney—nephrolithiasis	0.0041	0.0186	CbGeAlD
Sirolimus—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00409	0.00757	CcSEcCtD
Sirolimus—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00406	0.00751	CcSEcCtD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00402	0.0168	CbGpPWpGaD
Sirolimus—CYP3A5—cortex of kidney—nephrolithiasis	0.00399	0.0181	CbGeAlD
Sirolimus—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00397	0.00735	CcSEcCtD
Sirolimus—FKBP1A—TGF-beta Receptor Signaling—SPP1—nephrolithiasis	0.00393	0.0164	CbGpPWpGaD
Sirolimus—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00384	0.00711	CcSEcCtD
Sirolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.0038	0.0159	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00368	0.0154	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00368	0.0154	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—ATP6V0A4—nephrolithiasis	0.00361	0.0151	CbGpPWpGaD
Sirolimus—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00354	0.00654	CcSEcCtD
Sirolimus—Tension—Hydrochlorothiazide—nephrolithiasis	0.00352	0.00651	CcSEcCtD
Sirolimus—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00348	0.00645	CcSEcCtD
Sirolimus—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00347	0.00642	CcSEcCtD
Sirolimus—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00345	0.00638	CcSEcCtD
Sirolimus—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00336	0.00622	CcSEcCtD
Sirolimus—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00333	0.00616	CcSEcCtD
Sirolimus—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00332	0.00614	CcSEcCtD
Sirolimus—Agitation—Hydrochlorothiazide—nephrolithiasis	0.0033	0.0061	CcSEcCtD
Sirolimus—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00328	0.00607	CcSEcCtD
Sirolimus—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00324	0.00599	CcSEcCtD
Sirolimus—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00322	0.00595	CcSEcCtD
Sirolimus—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00321	0.00594	CcSEcCtD
Sirolimus—CYP3A4—renal system—nephrolithiasis	0.00318	0.0144	CbGeAlD
Sirolimus—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00317	0.00587	CcSEcCtD
Sirolimus—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00315	0.00584	CcSEcCtD
Sirolimus—Cough—Hydrochlorothiazide—nephrolithiasis	0.00313	0.00579	CcSEcCtD
Sirolimus—CYP3A4—kidney—nephrolithiasis	0.00307	0.0139	CbGeAlD
Sirolimus—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00305	0.00565	CcSEcCtD
Sirolimus—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00305	0.00565	CcSEcCtD
Sirolimus—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00305	0.00565	CcSEcCtD
Sirolimus—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00304	0.00563	CcSEcCtD
Sirolimus—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00302	0.00558	CcSEcCtD
Sirolimus—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00295	0.00546	CcSEcCtD
Sirolimus—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00293	0.00542	CcSEcCtD
Sirolimus—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00293	0.00542	CcSEcCtD
Sirolimus—Shock—Hydrochlorothiazide—nephrolithiasis	0.00288	0.00533	CcSEcCtD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00288	0.012	CbGpPWpGaD
Sirolimus—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00287	0.00531	CcSEcCtD
Sirolimus—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00286	0.00529	CcSEcCtD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00283	0.0118	CbGpPWpGaD
Sirolimus—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00283	0.00524	CcSEcCtD
Sirolimus—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00279	0.00516	CcSEcCtD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00279	0.0117	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00279	0.0117	CbGpPWpGaD
Sirolimus—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00274	0.00506	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00267	0.00494	CcSEcCtD
Sirolimus—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00265	0.0049	CcSEcCtD
Sirolimus—FGF2—Integrins in angiogenesis—SPP1—nephrolithiasis	0.00263	0.011	CbGpPWpGaD
Sirolimus—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00263	0.00487	CcSEcCtD
Sirolimus—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00261	0.00483	CcSEcCtD
Sirolimus—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.0026	0.00482	CcSEcCtD
Sirolimus—FGF2—Endochondral Ossification—SPP1—nephrolithiasis	0.0026	0.0109	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00259	0.0108	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00259	0.0108	CbGpPWpGaD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00259	0.0108	CbGpPWpGaD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00259	0.0108	CbGpPWpGaD
Sirolimus—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00258	0.00477	CcSEcCtD
Sirolimus—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00255	0.00471	CcSEcCtD
Sirolimus—Pain—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00463	CcSEcCtD
Sirolimus—Constipation—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00463	CcSEcCtD
Sirolimus—ABCB1—nephron tubule—nephrolithiasis	0.00248	0.0112	CbGeAlD
Sirolimus—EIF4E—BDNF signaling pathway—SPP1—nephrolithiasis	0.00244	0.0102	CbGpPWpGaD
Sirolimus—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00241	0.00446	CcSEcCtD
Sirolimus—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00239	0.00443	CcSEcCtD
Sirolimus—CYP3A7—Biological oxidations—SLC26A1—nephrolithiasis	0.00233	0.00975	CbGpPWpGaD
Sirolimus—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00231	0.00428	CcSEcCtD
Sirolimus—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00231	0.00428	CcSEcCtD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00231	0.00967	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00231	0.00967	CbGpPWpGaD
Sirolimus—ABCB1—renal system—nephrolithiasis	0.00225	0.0102	CbGeAlD
Sirolimus—ABCB1—kidney—nephrolithiasis	0.00218	0.00987	CbGeAlD
Sirolimus—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00216	0.00399	CcSEcCtD
Sirolimus—ABCB1—cortex of kidney—nephrolithiasis	0.00212	0.00961	CbGeAlD
Sirolimus—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.0021	0.00389	CcSEcCtD
Sirolimus—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00207	0.00383	CcSEcCtD
Sirolimus—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.002	0.00371	CcSEcCtD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00196	0.00821	CbGpPWpGaD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00196	0.00821	CbGpPWpGaD
Sirolimus—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00194	0.00358	CcSEcCtD
Sirolimus—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00186	0.00344	CcSEcCtD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00185	0.00773	CbGpPWpGaD
Sirolimus—Rash—Hydrochlorothiazide—nephrolithiasis	0.00185	0.00342	CcSEcCtD
Sirolimus—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00184	0.00341	CcSEcCtD
Sirolimus—Headache—Hydrochlorothiazide—nephrolithiasis	0.00183	0.00339	CcSEcCtD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00183	0.00764	CbGpPWpGaD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00183	0.00764	CbGpPWpGaD
Sirolimus—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00174	0.00322	CcSEcCtD
Sirolimus—CYP3A5—Biological oxidations—SLC26A1—nephrolithiasis	0.00169	0.00705	CbGpPWpGaD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00163	0.00681	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00162	0.00676	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00162	0.00676	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ADCY10—nephrolithiasis	0.00159	0.00665	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00144	0.00602	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—RGS14—nephrolithiasis	0.00135	0.00565	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00132	0.00551	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00132	0.00551	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ADCY10—nephrolithiasis	0.00117	0.00488	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—SPP1—nephrolithiasis	0.00113	0.00471	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—SLC26A1—nephrolithiasis	0.00107	0.00449	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—SPP1—nephrolithiasis	0.00101	0.00421	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000998	0.00417	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000998	0.00417	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RGS14—nephrolithiasis	0.000991	0.00415	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—ATP6V0A4—nephrolithiasis	0.000956	0.004	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000928	0.00388	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000928	0.00388	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000913	0.00382	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—DGKH—nephrolithiasis	0.000913	0.00382	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ADCY10—nephrolithiasis	0.000884	0.0037	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—SPP1—nephrolithiasis	0.000836	0.0035	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—SPP1—nephrolithiasis	0.000836	0.00349	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000827	0.00346	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000827	0.00346	CbGpPWpGaD
Sirolimus—FGF2—Disease—SLC26A1—nephrolithiasis	0.000813	0.0034	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000809	0.00338	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000809	0.00338	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000784	0.00328	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RGS14—nephrolithiasis	0.000751	0.00314	CbGpPWpGaD
Sirolimus—FGF2—Disease—ATP6V0A4—nephrolithiasis	0.000725	0.00303	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000721	0.00301	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00067	0.0028	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—DGKH—nephrolithiasis	0.00067	0.0028	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000661	0.00276	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CHRM3—nephrolithiasis	0.00066	0.00276	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000659	0.00276	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000659	0.00276	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ADCY10—nephrolithiasis	0.000656	0.00274	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PTH—nephrolithiasis	0.000604	0.00252	CbGpPWpGaD
Sirolimus—MTOR—Disease—SLC26A1—nephrolithiasis	0.000603	0.00252	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GRHPR—nephrolithiasis	0.000573	0.0024	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RGS14—nephrolithiasis	0.000558	0.00233	CbGpPWpGaD
Sirolimus—MTOR—Disease—ATP6V0A4—nephrolithiasis	0.000538	0.00225	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GRHPR—nephrolithiasis	0.000526	0.0022	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AGXT—nephrolithiasis	0.000511	0.00214	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—DGKH—nephrolithiasis	0.000507	0.00212	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000507	0.00212	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.0005	0.00209	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.0005	0.00209	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CHRM3—nephrolithiasis	0.000484	0.00202	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AGXT—nephrolithiasis	0.000469	0.00196	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000464	0.00194	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000464	0.00194	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTH—nephrolithiasis	0.000443	0.00185	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—APRT—nephrolithiasis	0.000435	0.00182	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—SLC26A1—nephrolithiasis	0.000435	0.00182	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000414	0.00173	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000414	0.00173	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SLC26A1—nephrolithiasis	0.000399	0.00167	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—APRT—nephrolithiasis	0.000399	0.00167	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GRHPR—nephrolithiasis	0.00038	0.00159	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000377	0.00157	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—DGKH—nephrolithiasis	0.000377	0.00157	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CHRM3—nephrolithiasis	0.000367	0.00153	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AGXT—nephrolithiasis	0.000339	0.00142	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTH—nephrolithiasis	0.000336	0.0014	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000331	0.00138	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AQP1—nephrolithiasis	0.00031	0.00129	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SPP1—nephrolithiasis	0.000303	0.00127	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—APRT—nephrolithiasis	0.000288	0.00121	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC26A1—nephrolithiasis	0.000288	0.00121	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GRHPR—nephrolithiasis	0.000287	0.0012	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AQP1—nephrolithiasis	0.000284	0.00119	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CHRM3—nephrolithiasis	0.00028	0.00117	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CHRM3—nephrolithiasis	0.000272	0.00114	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CHRM3—nephrolithiasis	0.000257	0.00107	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AGXT—nephrolithiasis	0.000256	0.00107	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTH—nephrolithiasis	0.000249	0.00104	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SPP1—nephrolithiasis	0.000222	0.00093	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—APRT—nephrolithiasis	0.000218	0.00091	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC26A1—nephrolithiasis	0.000218	0.00091	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AQP1—nephrolithiasis	0.000205	0.000859	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CHRM3—nephrolithiasis	0.000186	0.000777	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000177	0.00074	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SPP1—nephrolithiasis	0.000168	0.000705	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AGXT—nephrolithiasis	0.000158	0.000659	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AQP1—nephrolithiasis	0.000155	0.000648	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CHRM3—nephrolithiasis	0.00014	0.000586	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	0.000134	0.000561	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APRT—nephrolithiasis	0.000134	0.000561	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SPP1—nephrolithiasis	0.000125	0.000523	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AQP1—nephrolithiasis	9.55e-05	0.000399	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CHRM3—nephrolithiasis	8.64e-05	0.000361	CbGpPWpGaD
